Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores

BACKGROUND: The prognosis of advanced pancreatic cancer (APC) is poor and differs considerably among patients. Therefore, it is clinically relevant to identify patients with APC who are more likely to benefit from palliative chemotherapy with reduced risk of toxicity. To date, there is no prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gargiulo, Piera, Dietrich, Daniel, Herrmann, Richard, Bodoky, György, Ruhstaller, Thomas, Scheithauer, Werner, Glimelius, Bengt, Berardi, Simona, Pignata, Sandro, Brauchli, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317152/
https://www.ncbi.nlm.nih.gov/pubmed/30636977
http://dx.doi.org/10.1177/1758835918818351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317152/
https://www.ncbi.nlm.nih.gov/pubmed/30636977
http://dx.doi.org/10.1177/1758835918818351

Ejemplares similares